Article ID Journal Published Year Pages File Type
5823894 Biochemical Pharmacology 2012 8 Pages PDF
Abstract
(A) ABCG2 confers gefitinib or pelitinib resistance. Intracellular efficiency of neratinib or vandetanib is not restricted by ABCG2. (B) EGFR inhibitors block ABCG2 function thereby reversing MDR.
Keywords
Related Topics
Health Sciences Pharmacology, Toxicology and Pharmaceutical Science Pharmacology
Preview
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance
Authors
, , , , , , , , , , , ,